10x Genomics (NASDAQ:TXG) Given New $14.00 Price Target at UBS Group

10x Genomics (NASDAQ:TXG - Free Report) had its price target trimmed by UBS Group from $20.00 to $14.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

TXG has been the topic of several other research reports. Citigroup decreased their target price on 10x Genomics from $35.00 to $23.00 and set a "buy" rating on the stock in a research note on Wednesday, October 30th. Leerink Partners cut shares of 10x Genomics from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $25.00 to $12.00 in a research report on Thursday. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday, February 1st. Barclays reduced their target price on shares of 10x Genomics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Finally, The Goldman Sachs Group reduced their price objective on 10x Genomics from $16.00 to $14.00 and set a "sell" rating on the stock in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $20.57.

10x Genomics Stock Up 3.1 %

Shares of TXG traded up $0.37 during trading on Thursday, reaching $12.31. 4,354,670 shares of the company traded hands, compared to its average volume of 1,977,831. The stock has a 50-day simple moving average of $14.68 and a 200-day simple moving average of $17.33. 10x Genomics has a twelve month low of $10.80 and a twelve month high of $51.22. The stock has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. On average, equities research analysts predict that 10x Genomics will post -1.43 EPS for the current year.

Institutional Trading of 10x Genomics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after acquiring an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of 10x Genomics during the third quarter worth about $35,000. Blue Trust Inc. increased its position in shares of 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after purchasing an additional 1,025 shares in the last quarter. Signaturefd LLC increased its position in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after purchasing an additional 1,452 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in 10x Genomics by 1,108.9% during the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company's stock worth $55,000 after buying an additional 2,240 shares during the period. Institutional investors and hedge funds own 84.68% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.